Skip to main content
Clinical Trials/NL-OMON48531
NL-OMON48531
Completed
Not Applicable

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected Adults - ACTHIVE-001

Academisch Medisch Centrum0 sites24 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Academisch Medisch Centrum
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 17, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Men and women, aged between 18 and 50 years on the day of screening.
  • 2\. Willing to comply with the requirements of the protocol and available for
  • follow\-up for the planned duration of the study.
  • 3\. Willing and able to give written informed consent.
  • 4\. Willing to undergo HIV testing, risk reduction counselling and receive HIV
  • test results, including the possibility of vaccine\-induced seropositivity
  • 5\. All individuals engaging in sexual activity that could lead to pregnancy
  • must commit to use of an effective method of contraception for four months
  • following Investigational Medicinal Product administration.
  • 6\. All female volunteers must be willing to undergo urine pregnancy tests.

Exclusion Criteria

  • 1\. Confirmed HIV\-1 or HIV\-2 infection
  • 2\. Self\-reported risk for HIV exposure or STIs prior to screening.
  • 3\. If female, pregnant or planning a pregnancy during the period of enrolment
  • until four months after the last study vaccination; or lactating.
  • 4\. Any clinically relevant medical condition that is considered in the opinion
  • of the investigator to make the volunteer unsuitable for participation in the
  • study (under which underlying haematological disorders, specified infectious
  • diseases, hyposplenia, auto\-immune diseases, bleeding disorders, seizure
  • disorders, immunodeficiency, gastrointestinal, hepatic and cardiopulmonary
  • disorders). This also includes a history of malignancy in the past five years

Outcomes

Primary Outcomes

Not specified

Similar Trials